Formulation Development
Evogene Announces Expanded Collaboration With Google Cloud to Integrate AI Agents Into ChemPass AI
Evogene Ltd. recently announced an expanded phase of its collaboration with Google Cloud. Under this new phase, the collaboration will focus on developing and integrating…
Synthace Collaborates With Charles River to Offer Global Pharma Industry More Robust, Faster & Cost-Effective Assays
Synthace recently announced a collaboration with Charles River Laboratories International, Inc. Under the collaboration, Charles River will give its clients access to Synthace’s transformative approach to…
Sobi Completes Acquisition of Arthrosi Therapeutics, Strengthening Pipeline Potential Treatment of Gout
Swedish Orphan Biovitrum AB (publ) Sobi and Arthrosi Therapeutics, Inc. recently announced the completion of the acquisition of Arthrosi by Sobi. Upon completion of the…
Evinova & Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development With Artificial Intelligence
Evinova recently announced Bristol Myers Squibb has signed an agreement to optimize clinical trials with Evinova’s AI-native clinical development platform. Under the terms of the…
NeoVac Announces Positive Results Demonstrating Superior Safety Profile of Next-Generation mRNA-LNP Vaccine Platform
NeoVac recently announced positive results from first-in-human Phase I/II clinical study of NeomiVac, its investigational mRNA-LNP COVID-19 vaccine candidate. The clinical findings, now publicly available as…
SynGenSys Introduces Liver.SET Synthetic Promoter Library for Liver-Specific Gene Expression for In Vivo Gene Therapies
SynGenSys recently announced the launch of its Liver.SET library of liver-specific synthetic promoters. Developed using SyngenSys’ proprietary informatics and computational design platform, the Liver.SET library…
Evogene & Shanghai Lishan Biopharmaceuticals Announce Exclusive Licensing Agreement for a Microbiome-Based Therapeutic for Renal & Lung Cancer
Evogene Ltd. and Shanghai Lishan Biopharmaceuticals Co., Ltd. recently announced that Biomica Ltd., Evogene’s subsidiary, and Lishan Biotech entered into an exclusive worldwide licensing agreement for…
Coherus Oncology Announces Clinical Supply Agreement to Evaluate Tagmokitug in Combination With Pasritamig
Coherus Oncology, Inc. recently announced a clinical supply agreement with Johnson & Johnson to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in…
Bracco Enters Cell Therapy Manufacturing With Cell Selection & Activation Technologies
Bracco Imaging recently announced its first expansion into the cell therapy space, driven by its expertise and newly developed applications of its long-established microbubble technology. Bracco's…
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc. recently announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241) evaluating NEO-811, a novel investigational molecular glue degrader, in…
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
Cellares recently announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and…
Alzheon Reports Plasma Biomarker Results From Phase 3 & 2 Studies, Validating First-in-Class Mechanism of Action & Underscoring Benefits in Cognition, Function & Brain Volume Protection in Alzheimer’s Patients
Alzheon, Inc. recently announced plasma biomarker analyses from its APOLLOE4 Phase 3 and Phase 2 clinical studies of valiltramiprosate/ALZ-801. New results offer robust evidence supporting the…
SPECIAL FEATURE - Artificial Intelligence in Drug Discovery, Development & Delivery
Contributor Cindy H. Dubin speaks with leading drug makers, device manufacturers, and contract organizations who dispel the myths around AI and Machine Learning in the pharma industry and share how they are using AI to streamline clinical trials, automate lab tests, optimize resource allocation, enhance development timelines, and improve patient-friendly dosage forms.
FORMULATION FORUM - Solid Oral Dosages: Controlled Release of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, review a few examples of controlled release excipients and their attributes from monolithic matrix tablets and polymeric coated tablets.
LEADERSHIP PANEL - Trends to Watch for in 2026
Contributor Cindy H. Dubin interviews life science leaders to discuss the role of AI in drug repurposing, the future of personalized medicine, the importance of sustainability, and how to keep pace with innovation amid real-time FDA reviews.
Sanofi’s Venglustat Met All Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease
Positive results from the LEAP2MONO Phase 3 study (clinical study identifier: NCT05222906) demonstrated that venglustat met the primary and three out of four key secondary…
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Piramal Pharma Solutions recently announce the successful development, scale-up, and commercialization of a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad,…
CONTROLLED RELEASE - Challenges in Consistent & Predictable Delivery of Drugs Using Oral Controlled Release Technologies
True Rogers, RPh, PhD, Matthias Knarr, PhD, and Mark Dreibelbis, PhD, say excipient selection is a key consideration within the QbD framework, particularly for CR technologies. Excipients must be chosen carefully to ensure they deliver the needed processability, quality, stability, and performance during and following the manufacture of dosage forms.
EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
Joel Latham, CEO of Incannex Healthcare, shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success.
CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
Venkata Indurthi, PhD, believes the success of Baby KJ provides a model that could be replicated many times over to treat people with ultra-rare genetic diseases.
